Section Arrow
IMNN.NASDAQ
- Imunon
(Financial Status)
Quotes are at least 15-min delayed:2025/03/28 00:17 EDT
Last
 1.14
+0.1 (+9.62%)
Day High 
1.18 
Prev. Close
1.04 
1-M High
1.1508 
Volume 
353.43K 
Bid
1.15
Ask
1.17
Day Low
1.05 
Open
1.05 
1-M Low
0.78 
Market Cap 
15.21M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.94 
20-SMA 0.91 
50-SMA 0.9 
52-W High 3.65 
52-W Low 0.64 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.62/-0.91
Enterprise Value
15.89M
Balance Sheet
Book Value Per Share
0.29
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.02
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed:2025/03/28 00:17 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting adifferentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.